- Home
- SLRN vs MRVI Comparison
SLRN vs MRVI Comparison
Compare SLRN & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRN
- MRVI
- Stock Information
- Founded
- SLRN 2020
- MRVI 2014
- Country
- SLRN United States
- MRVI United States
- Employees
- SLRN N/A
- MRVI N/A
- Industry
- SLRN Biotechnology: Pharmaceutical Preparations
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SLRN Health Care
- MRVI Health Care
- Exchange
- SLRN Nasdaq
- MRVI Nasdaq
- Market Cap
- SLRN 224.6M
- MRVI 262.9M
- IPO Year
- SLRN 2023
- MRVI 2020
- Fundamental
- Price
- SLRN $2.09
- MRVI $2.06
- Analyst Decision
- SLRN Hold
- MRVI Hold
- Analyst Count
- SLRN 5
- MRVI 10
- Target Price
- SLRN $9.60
- MRVI $6.84
- AVG Volume (30 Days)
- SLRN 743.1K
- MRVI 1.8M
- Earning Date
- SLRN 05-23-2025
- MRVI 05-12-2025
- Dividend Yield
- SLRN N/A
- MRVI N/A
- EPS Growth
- SLRN N/A
- MRVI N/A
- EPS
- SLRN N/A
- MRVI N/A
- Revenue
- SLRN N/A
- MRVI $241,856,000.00
- Revenue This Year
- SLRN $267.11
- MRVI N/A
- Revenue Next Year
- SLRN N/A
- MRVI $11.14
- P/E Ratio
- SLRN N/A
- MRVI N/A
- Revenue Growth
- SLRN N/A
- MRVI N/A
- 52 Week Low
- SLRN $1.85
- MRVI $1.67
- 52 Week High
- SLRN $7.25
- MRVI $11.56
- Technical
- Relative Strength Index (RSI)
- SLRN 38.38
- MRVI 47.79
- Support Level
- SLRN $2.34
- MRVI $1.96
- Resistance Level
- SLRN $2.64
- MRVI $2.16
- Average True Range (ATR)
- SLRN 0.19
- MRVI 0.13
- MACD
- SLRN -0.01
- MRVI 0.04
- Stochastic Oscillator
- SLRN 6.61
- MRVI 25.97
About SLRN ACELYRIN INC.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.